Document Detail


Effects of eplerenone versus losartan in patients with low-renin hypertension.
MedLine Citation:
PMID:  16169319     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Sodium retention and volume expansion, mediated in part by aldosterone, are prominent features in low-renin hypertension. Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension.
METHODS: This 16-week, multicenter, double-blind, active-controlled, parallel-group, titration-to-effect trial compared the blood pressure and neurohumoral responses of the selective aldosterone blocker eplerenone (100-200 mg/d; n = 86) with those of the angiotensin receptor blocker losartan (50-100 mg/d; n = 82) in patients with low-renin hypertension (active renin < or = 25 pg/mL [< or = 42.5 mU/L]). Patients with diastolic blood pressure > or = 90 mm Hg after 8 weeks of monotherapy received add-on therapy with hydrochlorothiazide 12.5 to 25 mg daily.
RESULTS: After 8 weeks of therapy, eplerenone reduced blood pressure to a greater extent than losartan (systolic blood pressure -15.8 vs -10.1 mm Hg, P = .017; diastolic blood pressure -9.3 vs -6.7 mm Hg, P = .05). After 16 weeks of therapy, significantly fewer eplerenone-treated patients (32.5%) than losartan-treated patients (55.6%) required add-on hydrochlorothiazide as allowed per protocol for blood pressure control (P = .003). Eplerenone consistently reduced blood pressure regardless of baseline active plasma renin levels whereas losartan reduced blood pressure more effectively in patients with higher baseline active renin levels. There were no differences between treatments in adverse events (reported by 62.8% of eplerenone patients and by 72.0% of losartan patients).
CONCLUSIONS: These data show that eplerenone was more effective than losartan in reducing blood pressure in patients with low-renin hypertension. Further studies evaluating the efficacy of eplerenone in difficult-to-treat or resistant hypertension are needed.
Authors:
Myron H Weinberger; William B White; Luis-Miguel Ruilope; Thomas M MacDonald; Robert C Davidson; Barbara Roniker; Jeffrey L Patrick; Scott L Krause
Related Documents :
980059 - Reciprocal relation between renin dependency and sodium dependency in essential hyperte...
8491049 - Response of vasoactive substances to reduction of blood volume during hemodialysis in h...
2650709 - Extrarenal renin and blood pressure regulation. an alternative viewpoint.
6340859 - Effect of captopril on blood pressure and on the renin-angiotensin-aldosterone system i...
191299 - The renin-angiotensin system and the central nervous system.
1057909 - Effect of high dose spironolactone and chlorthalidone in essential hypertension: relati...
2883809 - Autoregulation of capillary pressure and filtration in cat skeletal muscle in states of...
20172449 - The e-wave delayed relaxation pattern to lv pressure contour relation: model-based pred...
16996599 - Effect of corneal thickness on dynamic contour, rebound, and goldmann tonometry.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  150     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-19     Completed Date:  2005-11-28     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  426-33     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin Receptor Antagonists*
Double-Blind Method
Female
Humans
Hypertension / blood,  drug therapy*
Losartan / therapeutic use*
Male
Middle Aged
Mineralocorticoid Receptor Antagonists / therapeutic use*
Renin / blood,  secretion
Spironolactone / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Mineralocorticoid Receptor Antagonists; 27O7W4T232/Spironolactone; 6995V82D0B/eplerenone; EC 3.4.23.15/Renin; JMS50MPO89/Losartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between lipid testing and statin therapy in acute myocardial infarction patients.
Next Document:  Long-term hormone replacement therapy does not cause increased platelet activation.